COVID-19 as a factor of pharmaceutical business development in Russia

The article examines the impact of the coronavirus pandemic on the development of the pharmaceutical business in Russia. Despite the fact that the general trend of covid has become a negative impact on almost all spheres and industries, the researchers note the fact that for fee-based medicine and the pharmaceutical market COVID-19 has become a driver of active development. In the course of the work, it was determined that the pharmaceutical business in Russia is at the stage of large-scale transformation, which COVID-19 has only accelerated. If previously the pharmaceutical market was characterized by conservatism and a low degree of flexibility to transformation, the pandemic has become a driver of its development through transformation and digitalization. Assessment of changes in the main economic indicators in the context of the top 10 market leaders in terms of revenue showed that the undoubted leader is JSC «R-Pharm», where the revenue has doubled. In addition, CJSC «Biocad» and JSC«Generium» have developed most dynamically in recent years. Among the top 10 market leaders in 2020, only two companies occupying positions 9-10 of the rating do not produce products relevant to the pandemic, while the first 8 make a significant contribution to the pharmaceutical market in this area. As a result, the COVID-19 pandemic has had a positive impact on the pharmaceutical market in Russia, forming a “covid” vector of its development and a new business cluster, which continues to receive active development, moreover, not without the participation of the state, since it is the state in the person of the health care system is the largest and only customer of mass production of vaccines.